Amy D. Harper

628 total citations
10 papers, 317 citations indexed

About

Amy D. Harper is a scholar working on Molecular Biology, Pediatrics, Perinatology and Child Health and Rehabilitation. According to data from OpenAlex, Amy D. Harper has authored 10 papers receiving a total of 317 indexed citations (citations by other indexed papers that have themselves been cited), including 6 papers in Molecular Biology, 4 papers in Pediatrics, Perinatology and Child Health and 3 papers in Rehabilitation. Recurrent topics in Amy D. Harper's work include Muscle Physiology and Disorders (6 papers), Infant Development and Preterm Care (3 papers) and Exercise and Physiological Responses (3 papers). Amy D. Harper is often cited by papers focused on Muscle Physiology and Disorders (6 papers), Infant Development and Preterm Care (3 papers) and Exercise and Physiological Responses (3 papers). Amy D. Harper collaborates with scholars based in United States, Canada and Russia. Amy D. Harper's co-authors include Jean K. Mah, Anne M. Connolly, Craig M. McDonald, Eric P. Hoffman, Edward C. Smith, Vamshi K. Rao, Craig M. Zaidman, Paula R. Clemens, Lauren P. Morgenroth and Taishi Yamashita and has published in prestigious journals such as Scientific Reports, American Journal Of Pathology and Physical Therapy.

In The Last Decade

Amy D. Harper

10 papers receiving 314 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Amy D. Harper United States 6 265 60 59 49 33 10 317
Pavel Balabanov Netherlands 8 257 1.0× 65 1.1× 66 1.1× 48 1.0× 26 0.8× 14 356
Kevin McCall United States 9 193 0.7× 84 1.4× 67 1.1× 100 2.0× 10 0.3× 11 354
D Jones United Kingdom 4 225 0.8× 65 1.1× 31 0.5× 41 0.8× 42 1.3× 4 280
Alexander P. Murphy United Kingdom 7 174 0.7× 37 0.6× 64 1.1× 41 0.8× 16 0.5× 14 213
Elke Hobbiebrunken Germany 8 133 0.5× 45 0.8× 35 0.6× 76 1.6× 6 0.2× 11 268
Hallie N. Nelson United States 4 319 1.2× 54 0.9× 36 0.6× 22 0.4× 19 0.6× 5 446
A. Seferian France 9 153 0.6× 76 1.3× 39 0.7× 20 0.4× 50 1.5× 28 230
Emanuela Abiusi Italy 7 214 0.8× 61 1.0× 254 4.3× 35 0.7× 11 0.3× 8 376
M. Kujawa Poland 9 120 0.5× 24 0.4× 12 0.2× 61 1.2× 29 0.9× 27 344
Ulrike Schara‐Schmidt Germany 9 157 0.6× 100 1.7× 28 0.5× 42 0.9× 8 0.2× 59 278

Countries citing papers authored by Amy D. Harper

Since Specialization
Citations

This map shows the geographic impact of Amy D. Harper's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Amy D. Harper with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Amy D. Harper more than expected).

Fields of papers citing papers by Amy D. Harper

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Amy D. Harper. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Amy D. Harper. The network helps show where Amy D. Harper may publish in the future.

Co-authorship network of co-authors of Amy D. Harper

This figure shows the co-authorship network connecting the top 25 collaborators of Amy D. Harper. A scholar is included among the top collaborators of Amy D. Harper based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Amy D. Harper. Amy D. Harper is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

10 of 10 papers shown
1.
Harper, Amy D., Haluk Topaloğlu, Eugenio Mercuri, et al.. (2024). Safety and efficacy of viltolarsen in ambulatory and nonambulatory males with Duchenne muscular dystrophy. Scientific Reports. 14(1). 23488–23488. 2 indexed citations
2.
Miller, Meagan, Richard D. Stevenson, Mary S. Shall, et al.. (2023). Impact of the COVID-19 Pandemic on a Clinical Trial: A Quantitative Report on Study Engagement and Strategies. Pediatric Physical Therapy. 35(4). 439–448. 1 indexed citations
3.
Butera, Christiana, Amy D. Harper, Karen D. Hendricks‐Muñoz, et al.. (2023). Factors Influencing Receipt and Type of Therapy Services in the NICU. Behavioral Sciences. 13(6). 481–481. 3 indexed citations
4.
Clemens, Paula R., Vamshi K. Rao, Anne M. Connolly, et al.. (2023). Efficacy and Safety of Viltolarsen in Boys With Duchenne Muscular Dystrophy: Results From the Phase 2, Open-Label, 4-Year Extension Study. Journal of Neuromuscular Diseases. 10(3). 439–447. 18 indexed citations
5.
Clemens, Paula R., Vamshi K. Rao, Anne M. Connolly, et al.. (2022). Long-Term Functional Efficacy and Safety of Viltolarsen in Patients with Duchenne Muscular Dystrophy. Journal of Neuromuscular Diseases. 9(4). 493–501. 38 indexed citations
6.
Kelly, Claire E., Deanne K. Thompson, Amy D. Harper, et al.. (2021). Longitudinal Changes in the Sensorimotor Pathways of Very Preterm Infants During the First Year of Life With and Without Intervention: A Pilot Study. Developmental Neurorehabilitation. 24(7). 448–455. 1 indexed citations
7.
8.
Clemens, Paula R., Vamshi K. Rao, Anne M. Connolly, et al.. (2020). Safety, Tolerability, and Efficacy of Viltolarsen in Boys With Duchenne Muscular Dystrophy Amenable to Exon 53 Skipping. JAMA Neurology. 77(8). 982–982. 179 indexed citations
9.
Wu, Bo, Sapana N. Shah, Peijuan Lu, et al.. (2018). Long-Term Treatment of Tamoxifen and Raloxifene Alleviates Dystrophic Phenotype and Enhances Muscle Functions of FKRP Dystroglycanopathy. American Journal Of Pathology. 188(4). 1069–1080. 27 indexed citations
10.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Pavel Balabanov Breakdown of academic impact, for papers by Kevin McCall Breakdown of academic impact, for papers by D Jones Breakdown of academic impact, for papers by Alexander P. Murphy Breakdown of academic impact, for papers by Elke Hobbiebrunken Breakdown of academic impact, for papers by Hallie N. Nelson Breakdown of academic impact, for papers by A. Seferian Breakdown of academic impact, for papers by Emanuela Abiusi Breakdown of academic impact, for papers by M. Kujawa Breakdown of academic impact, for papers by Ulrike Schara‐Schmidt
Rankless by CCL
2026